Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07HTX
|
|||
Former ID |
DIB016248
|
|||
Drug Name |
GL-331
|
|||
Synonyms |
GL-331; UNII-0I81858VSZ; 127882-73-9; 0I81858VSZ; NSC628672; NSC 628672; AC1L3WEV; CHEMBL283631; SCHEMBL5953587; DTXSID40155689; ZINC8652994; 5,8,8a,9-Tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-((4-nitrophenyl)amino)-furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, (5R-(5alpha,5abeta,8aalpha,9beta))-; (5R-(5alpha,5abeta,8aalpha,9beta))-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-((4-nitrophenyl)amino)furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Colorectal cancer [ICD-11: 2B91.Z] | Discontinued in Phase 2 | [1] | |
Company |
University of North Carolina
|
|||
Structure |
Download2D MOL |
|||
Formula |
C27H24N2O9
|
|||
Canonical SMILES |
COC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)NC6=CC=C(C=C6)[N+](=O)[O-]
|
|||
InChI |
1S/C27H24N2O9/c1-34-21-7-13(8-22(35-2)26(21)30)23-16-9-19-20(38-12-37-19)10-17(16)25(18-11-36-27(31)24(18)23)28-14-3-5-15(6-4-14)29(32)33/h3-10,18,23-25,28,30H,11-12H2,1-2H3/t18-,23+,24-,25+/m0/s1
|
|||
InChIKey |
DLROLUIVVKTFPW-LVEBQJTPSA-N
|
|||
CAS Number |
CAS 127882-73-9
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | DNA topoisomerase II (TOP2) | Target Info | Modulator | [2], [3] |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002538) | |||
REF 2 | GL331, a topoisomerase II inhibitor, induces radiosensitization of human glioma cells. Anticancer Res. 2006 May-Jun;26(3A):2149-56. | |||
REF 3 | Induction of apoptosis and cell cycle arrest in glioma cells by GL331 (a topoisomerase II inhibitor). Anticancer Res. 2005 Nov-Dec;25(6B):4203-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.